Replies to post #604 on ImmunoGen Inc (IMGN)

[XenaLives]

I believe the EU and the rest of the world are becoming more data driven i their approvals. Also risk/reward is an issue when they believe a drug does not increase risk but can save lives and healthcare system dollars.

Unfortunately saved lives and quality of life are less important in our pay for play system.

[XenaLives]

Institutional interest is around 75%. I believe that the biggest reason for this battering is they want retail OUT of IMGN.